Nothing Special   »   [go: up one dir, main page]

WO2001076639A3 - Chemically-modified myelopoietin conjugates - Google Patents

Chemically-modified myelopoietin conjugates Download PDF

Info

Publication number
WO2001076639A3
WO2001076639A3 PCT/US2001/011256 US0111256W WO0176639A3 WO 2001076639 A3 WO2001076639 A3 WO 2001076639A3 US 0111256 W US0111256 W US 0111256W WO 0176639 A3 WO0176639 A3 WO 0176639A3
Authority
WO
WIPO (PCT)
Prior art keywords
modified
chemically
myelopoietin
conjugates
mpo
Prior art date
Application number
PCT/US2001/011256
Other languages
French (fr)
Other versions
WO2001076639A2 (en
Inventor
Rory Finn
Yatin Gokarn
Robert Hills
Peter Nicastro
Hong Qi
Kurt Sedo
Ned Siegel
Smith Walter
Original Assignee
Pharmacia Corp
Rory Finn
Yatin Gokarn
Robert Hills
Peter Nicastro
Hong Qi
Kurt Sedo
Ned Siegel
Smith Walter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp, Rory Finn, Yatin Gokarn, Robert Hills, Peter Nicastro, Hong Qi, Kurt Sedo, Ned Siegel, Smith Walter filed Critical Pharmacia Corp
Priority to AU2001289307A priority Critical patent/AU2001289307A1/en
Publication of WO2001076639A2 publication Critical patent/WO2001076639A2/en
Publication of WO2001076639A3 publication Critical patent/WO2001076639A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a chemically modified Myelopoietin (MPO) prepared by binding a water soluble polymer to the protein. The chemically-modified protein according to the present invention may have a much longer lasting neutrophil-increasing activity than that of the un-modified MPO, enabling reduced dose and scheduling opportunities.
PCT/US2001/011256 2000-04-06 2001-04-06 Chemically-modified myelopoietin conjugates WO2001076639A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001289307A AU2001289307A1 (en) 2000-04-06 2001-04-06 Chemically-modified myelopoietin conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19549600P 2000-04-06 2000-04-06
US60/195,496 2000-04-06

Publications (2)

Publication Number Publication Date
WO2001076639A2 WO2001076639A2 (en) 2001-10-18
WO2001076639A3 true WO2001076639A3 (en) 2002-05-10

Family

ID=22721621

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011256 WO2001076639A2 (en) 2000-04-06 2001-04-06 Chemically-modified myelopoietin conjugates

Country Status (2)

Country Link
AU (1) AU2001289307A1 (en)
WO (1) WO2001076639A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969042B2 (en) 2004-08-19 2015-03-03 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
US9138461B2 (en) 2007-05-01 2015-09-22 Biogen Ma Inc. Compositions and methods for increasing vascularization

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04004809A (en) * 2001-11-20 2004-08-11 Pharmacia Corp Chemically-modified human growth hormone conjugates.
WO2005085283A1 (en) * 2004-03-03 2005-09-15 Yamanouchi Pharmaceutical Co., Ltd. Modified interleukin-11 and medicinal composition containing the same
EP1848461A2 (en) 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
TWI501774B (en) 2006-02-27 2015-10-01 Biogen Idec Inc Treatments for neurological disorders
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8110651B2 (en) 2008-01-11 2012-02-07 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012874A2 (en) * 1989-04-21 1990-11-01 Genetics Institute, Inc. Cysteine added variants of polypeptides and chemical modifications thereof
WO1994012639A2 (en) * 1992-11-24 1994-06-09 G. D. Searle & Co. Interleukin-3 (il-3) mutant polypeptides
WO1995021197A1 (en) * 1994-02-04 1995-08-10 G.D. Searle & Co. Il-3 variant hematopoiesis fusion protein
WO1996011953A1 (en) * 1994-10-12 1996-04-25 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6022535A (en) * 1993-11-22 2000-02-08 G. D. Searle & Company Treatment of hematopoietic disorders with fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012874A2 (en) * 1989-04-21 1990-11-01 Genetics Institute, Inc. Cysteine added variants of polypeptides and chemical modifications thereof
WO1994012639A2 (en) * 1992-11-24 1994-06-09 G. D. Searle & Co. Interleukin-3 (il-3) mutant polypeptides
US6022535A (en) * 1993-11-22 2000-02-08 G. D. Searle & Company Treatment of hematopoietic disorders with fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors
WO1995021197A1 (en) * 1994-02-04 1995-08-10 G.D. Searle & Co. Il-3 variant hematopoiesis fusion protein
WO1996011953A1 (en) * 1994-10-12 1996-04-25 Amgen Inc. N-terminally chemically modified protein compositions and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRANCIS G E ET AL: "PEGYLATION OF CYTOKINES AND OTHER THERAPEUTIC PROTEINS AND PEPTIDES: THE IMPORTANCE OF BIOLOGICAL OPTIMISATION OF COUPLING TECHNIQUES", INTERNATIONAL JOURNAL OF HEMATOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 68, no. 1, July 1998 (1998-07-01), pages 1 - 18, XP000791226, ISSN: 0925-5710 *
ZALIPSKY S: "FUNCTIONALIZED POLY(ETHYLENE GLYCOL) FOR PREPARATION OF BIOLOGICALLY RELEVANT CONJUGATES", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 6, no. 2, 1995, pages 150 - 165, XP002068523, ISSN: 1043-1802 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969042B2 (en) 2004-08-19 2015-03-03 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
US9138461B2 (en) 2007-05-01 2015-09-22 Biogen Ma Inc. Compositions and methods for increasing vascularization

Also Published As

Publication number Publication date
WO2001076639A2 (en) 2001-10-18
AU2001289307A1 (en) 2001-10-23

Similar Documents

Publication Publication Date Title
WO2003044056A3 (en) Chemically-modified human growth hormone conjugates
WO2005000359A3 (en) Chemically-modified human growth hormone conjugates
BR0209242A (en) Starch functional aminopolidiorganosiloxanes
DE59906975D1 (en) AQUEOUS REACTIVE SPACHTELMASSEN (I)
WO2001079461A3 (en) Polypeptides having haloperoxidase activity
WO2004029207A3 (en) Optimized fc variants and methods for their generation
IL161412A0 (en) Glycoprotein compositions
WO2003015694A3 (en) Agents for enhancing the immune response
WO2003000038A3 (en) Compositions and methods for modulating plant development
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
AU8859498A (en) Thermosetting aqueous compositions
ZA200209049B (en) Oxidising composition for treating keratin fibres, comprising a particular aminosilicone.
ZA200208489B (en) Salt-sensitive, water-dispersible polymer composition.
WO2001076639A3 (en) Chemically-modified myelopoietin conjugates
ZA200208766B (en) Reducing composition for treating keratin fibres, comprising a particular aminosilicone.
AU2003302165A1 (en) Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
WO2003000179A3 (en) Chemically-modified progenipoietin conjugates
WO2002030472A3 (en) Compositions for release of radiosensitizers, and methods of making and using the same
AU2001288236A1 (en) Natural, non-allergenic, immune system stimulant
WO2003057712A3 (en) Humanized lactoferrin and uses thereof
BG103175A (en) Water soluble compound and cellulose-containing granulates
ID27733A (en) METHODIMINOFENILASETAMIDA
WO2004075028A3 (en) Systems and methods for variable rebate and incentive programs
HK1049485A1 (en) DithiepinoÄ6,5-BÜpyridines, and related compositions, methods of producing and uses.
MXPA04002104A (en) Antibodies against caspase-8, their preparation and use.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP